Isoray (NYSEAMERICAN:ISR) Stock Rating Lowered by Zacks Investment Research

Isoray (NYSEAMERICAN:ISRGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “IsoRay, Inc. is a medical technology company that produces therapeutic radioactive isotopes. Through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company’s Proxcelan Cesium-131 seed is classified as a Class II device. The Company competes with Varian Medical Systems, Siemens Healthcare, Elekta AB and Accuray Incorporated. “

Shares of Isoray stock opened at $0.30 on Thursday. Isoray has a 52-week low of $0.25 and a 52-week high of $0.94. The stock has a market cap of $42.60 million, a PE ratio of -6.00 and a beta of 0.92.

Isoray (NYSEAMERICAN:ISRGet Rating) last issued its quarterly earnings results on Tuesday, May 10th. The healthcare company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). Isoray had a negative net margin of 48.05% and a negative return on equity of 9.19%. Research analysts predict that Isoray will post -0.04 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in ISR. Perkins Capital Management Inc. lifted its stake in shares of Isoray by 80.4% during the fourth quarter. Perkins Capital Management Inc. now owns 2,801,000 shares of the healthcare company’s stock valued at $1,086,000 after buying an additional 1,248,000 shares during the period. Highland Private Wealth Management lifted its stake in shares of Isoray by 14.8% during the fourth quarter. Highland Private Wealth Management now owns 972,038 shares of the healthcare company’s stock valued at $377,000 after buying an additional 125,000 shares during the period. Bard Associates Inc. lifted its stake in shares of Isoray by 8.1% during the first quarter. Bard Associates Inc. now owns 669,200 shares of the healthcare company’s stock valued at $243,000 after buying an additional 50,000 shares during the period. State Street Corp lifted its stake in shares of Isoray by 6.7% during the first quarter. State Street Corp now owns 553,619 shares of the healthcare company’s stock valued at $201,000 after buying an additional 34,577 shares during the period. Finally, Taylor & Morgan Wealth Management LLC lifted its stake in shares of Isoray by 61.8% during the first quarter. Taylor & Morgan Wealth Management LLC now owns 550,000 shares of the healthcare company’s stock valued at $200,000 after buying an additional 210,000 shares during the period. 11.16% of the stock is currently owned by institutional investors.

About Isoray (Get Rating)

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.

Read More

Get a free copy of the Zacks research report on Isoray (ISR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with MarketBeat.com's FREE daily email newsletter.